BioSpace News Archive

At a meeting with analysts and investors at its Investor Day, members of the executive leadership team of Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, will discuss the company’s priorities to grow revenues and create shareholder value.

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the first participant was enrolled in the Phase 2 ‘UPLIFT’ study of TNX-601 ER1 (tianeptine hemioxalate extended-release tablets) for the treatment of major depressive disorder (MDD).

TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today highlights six studies published in 2022.

Purple Biotech Ltd. today provided new results from exploratory analyses conducted as part of a Phase 1 dose escalation study that assessed the safety and tolerability of CM24 plus nivolumab (NCT04731467).

Acurx Pharmaceuticals, Inc. announced today certain financial and operational results for the fourth quarter and full year ended December 31 , 2022.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, highlighted pipeline and business progress and fourth quarter and full year 2022 financial results.

ADMA Biologics, Inc. today announced that it will report fourth quarter and full year 2022 financial results on March 23, 2023, after the U.S. financial markets close.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD Vaginal Panel on the BD COR™ System.

Bio-Path Holdings, Inc., a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, provides a clinical development and operational update.